Global Hypopituitarism Treatment Market - 2023-2030

Global Hypopituitarism Treatment Market - 2023-2030

Global Hypopituitarism Treatment Market reached US$ XX billion in 2022 and is expected to reach US$ XX million by 2030 growing at a CAGR of XX% during the forecast period 2023-2030.

Hypopituitarism occurs when the pituitary gland is not active and does not make enough hormones. Hypopituitarism can directly affect the pituitary gland or can indirectly affect the gland through changes in the hypothalamus.

The hormones released by the pituitary gland include antidiuretic hormone, growth hormone, follicle-stimulating hormone, and oxytocin. The lack of a hormone leads to loss of function in the gland or organ the hormone controls. For example, lack of thyroid-stimulating hormone (TSH) leads to loss of normal function of the thyroid gland.

Market Dynamics

Increasing number of pituitary tumor cases

The increasing prevalence of pituitary tumors that can cause hypopituitarism acts as a significant driver for market growth. Pituitary tumors are unusual growths that develop in the pituitary gland. Most pituitary tumors are benign and can be treated by removing with surgery or can be controlled with medications or radiation therapy.

For instance, according to John Hopkins Medicine, around 1 in 10 people develop a pituitary adenoma in their lifetime. About 13,900 pituitary gland tumors were diagnosed in the United States in 2023 by making up about 17% of all primary brain tumors.

Additionally, according to the American Cancer Society Report, more than 10,000 pituitary tumors are diagnosed each year in the United States. Almost all of these tumors are benign and only a few pituitary tumors are cancerous.

Furthermore, significant growth drivers such as the rising clinical trials for hypopituitarism drugs, and the development of growth hormones are expected to drive the market in the forecast period.

Side effects associated with treatment medications

The treatment medications can cause sleepiness, vertigo, nausea, vomiting, diarrhea or constipation, headaches, disorientation, and depression as adverse effects. Additionally, growth hormone deficiency can cause growth problems and short stature and can lead to Muscle weakness, fatigue, and changes in body fat.

Segment Analysis

The global hypopituitarism treatment market is segmented based on type, treatment, end user, and region.

The hormone replacement therapy segment accounted for approximately 56.8% of the market share

The hormone replacement segment is expected to hold the largest market share over the period forecast due to the increasing number of clinical trials. A total number of 189 clinical trials were conducted for hypopituitarism treatment.

For instance, according to clinicaltrial.gov, on February 8, 2023, the Center for Neurological Studies in collaboration with Novo Nordisk A/S started a clinical trial on growth hormone replacement therapy for retired professional football players. The condition includes anterior pituitary hyposecretion syndrome and hypopituitarism. The expected study completion date is March 2025.

Additionally, on December 5, 2023, Novo Nordisk A/S started a clinical trial on the efficacy and safety of once-weekly (Somapacitan) treatment compared to daily growth hormone treatment (Norditropin FlexPro) in children with growth hormone treatment. The expected study completion date is September 2024. Hence, due to the above factors, the segment is expected to hold the largest market share.

Geographical Analysis

North America is expected to hold a significant position in the global hypopituitarism treatment market share

The global hypopituitarism treatment market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa. North America has maintained a significant market proportion due to factors such as the rising prevalence of hypopituitarism, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.

For instance, hypopituitarism is listed as a rare disorder by the National Institutes of Health affecting less than 200,000 individuals in the United States. Globally, hypopituitarism has an estimated incidence of 4.2 cases per 100,000 per year and an estimated prevalence of 45.5 cases per 100,000.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the global hypopituitarism treatment market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatment, drug launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the hypopituitarism treatment market is expected to be moderately affected over the forecast period.

Market Segmentation

By Type
• Isolated pituitary deficiency
• Multiple pituitary hormone deficiency
• Panhypopituitarism

By Treatment
• Hormone Replacement Therapy
Hydrocortisone (Cortef)
Prednisone (Rayos)
Levothyroxine (Levoxyl)
Growth Hormones
Fertility Hormones
• Surgery
• Radiation therapy

By End User
• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Pfizer Inc., Horizon Therapeutics Plc., Viatris Inc., AbbVie Inc., Weefsel Pharma, Teva Pharmaceutical Industries Ltd., Fresenius SE & Co KGaA, Omicron Pharma Pvt Ltd., and Strides Pharma Science Limited among others.

Key Developments
• In June 2023, the U.S FDA approved Pfizer and OPKO Health’s injectable hormone therapy called Ngenla for the treatment of pediatric patients suffering from growth hormone deficiency.

Why Purchase the Report?
• To visualize the global hypopituitarism treatment market segmentation based on type, treatment, end users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global hypopituitarism treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global hypopituitarism treatment market report would provide approximately 61 tables, 69 figures, and 185 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies